Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria

Iptacopan, an oral Factor B inhibitor, is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In clinical trials it was safe and effective but real-world data, particularly in patients with associated bone marrow failure, remain limited. A retrospective, multicenter study was conducted in patients with PNH who received iptacopan monotherapy in the UK and France between July 2021 and July 2025. Patient demographics, prior treatment and indication for switch were collected, as were hematological parameters at baseline, 3, 12 and 24 months. Outcomes included breakthrough hemolysis, infections, thrombotic events, treatment discontinuation and death. A total of 151 patients were included with a median treatment duration of 238 days. Iptacopan produced significant increases in mean hemoglobin, from 104 g/L at baseline to 127 g/L at 3 months, with improvements sustained to 24 months. A total of 76% achieved a hemoglobin ≥ 120 g/L by 12 months, compared with 21.9% at baseline, with transfusion independency in 88%. There was no statistical difference in responses between patients with and without history of bone marrow failure. Breakthrough hemolysis occurred in 6.6% of patients, with a mean hemoglobin fall of 24 g/L. Suspected bacterial infections occurred at a rate of 0.18 per patient-year, but there were no meningococcal or pneumococcal infections. There were no thromboses, and no deaths related to iptacopan. This cohort demonstrates that iptacopan produces sustained improvements in patients with PNH, irrespective of prior complement inhibition or history of bone marrow failure. Longer follow-up is needed to characterize long-term efficacy and infection risk.

Authors

Institutions

Publication Details

Journal
American Journal of Hematology
Published
2026-10-27
DOI
https://doi.org/10.1002/ajh.70531
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria

Michael L. Loschi, Talha Munir, Joanna Large, Morag Griffin et al.
5 links
American Journal of Hematology
Complement system in diseases
article

Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria

Michael L. Loschi, Talha Munir, Joanna Large, Morag Griffin, Petra Muus, Roochi Trikha, Francesco Versino, Alice Garnier, Austin Gladston Kulasekararaj, Yosr Hicheri, Isabelle Brindel, Marc Michel, Sateesh Kumar Nagumantry, Alexandra Pike, Simona Pagliuca, Shreyans Gandhi, Flore Sicre de Fontbrune, Régis Peffault de Latour, Édouard Forcade, Lynda Maafa, Richard J. Kelly, Louise Arnold, Matthew Holt
article en

Abstract

Iptacopan, an oral Factor B inhibitor, is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In clinical trials it was safe and effective but real-world data, particularly in patients with associated bone marrow failure, remain limited. A retrospective, multicenter study was conducted in patients with PNH who received iptacopan monotherapy in the UK and France between July 2021 and July 2025. Patient demographics, prior treatment and indication for switch were collected, as were hematological parameters at baseline, 3, 12 and 24 months. Outcomes included breakthrough hemolysis, infections, thrombotic events, treatment discontinuation and death. A total of 151 patients were included with a median treatment duration of 238 days. Iptacopan produced significant increases in mean hemoglobin, from 104 g/L at baseline to 127 g/L at 3 months, with improvements sustained to 24 months. A total of 76% achieved a hemoglobin ≥ 120 g/L by 12 months, compared with 21.9% at baseline, with transfusion independency in 88%. There was no statistical difference in responses between patients with and without history of bone marrow failure. Breakthrough hemolysis occurred in 6.6% of patients, with a mean hemoglobin fall of 24 g/L. Suspected bacterial infections occurred at a rate of 0.18 per patient-year, but there were no meningococcal or pneumococcal infections. There were no thromboses, and no deaths related to iptacopan. This cohort demonstrates that iptacopan produces sustained improvements in patients with PNH, irrespective of prior complement inhibition or history of bone marrow failure. Longer follow-up is needed to characterize long-term efficacy and infection risk.

American Journal of Hematology
University of Leeds (GB), King's College London (GB), Peterborough City Hospital (GB), St James's University Hospital (GB), Centre Hospitalier Universitaire de Bordeaux (FR), Centre Hospitalier Universitaire de Nice (FR), Centre Hospitalier Universitaire de Nantes (FR), Centre Hospitalier Universitaire Henri-Mondor (FR), National Institute for Health and Care Research (GB), Assistance Publique – Hôpitaux de Paris (FR), European Society for Blood and Marrow Transplantation (NL), Centre Hospitalier Régional et Universitaire de Nancy (FR), King's College Hospital NHS Foundation Trust (GB), Hôpitaux Universitaires Henri-Mondor (FR), Hôpital Saint-Louis (FR), Institut Paoli-Calmettes (FR), King's College Hospital (GB), European Society for Blood and Marrow Transplantation (FR)
Good health and well-being
Openalex Percentile: Top 19%
Complement system in diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon